

REMARKS

Formal Matters

Claims 1-51 are pending after entry of the amendments set forth herein.

Claims 9, 13, 18, 23, 25-28, 33, 36, 38, 39, 40, 41-43, 46-49, and 51 are amended, as shown below. A complete listing of the claims in this case, with their status, is shown below.

Amendments to the Specification are made to insert the Abstract as a separate page, and to insert the Sequence Listing. Support for the abstract is found in the abstract of the PCT application as filed.

No new matter has been added.

Certification Regarding Sequence Listing

I hereby certify that the enclosed Sequence Listing is being submitted under 37 CFR §§ 1.821(c) and (e) in paper and computer readable form (Compact Disk labeled 'CRF').

As required by 37 CFR 1.821(f), I hereby state that the content of the paper and computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e) are the same. The Computer Readable Format (CRF), being submitted under 37 CFR §§ 1.52(e) and 1.824, is formatted on IBM-PC, the operating system compatibility is MS-Windows and the file listing is:


Seqlist.txt 17 KB created May 5, 2005

I hereby certify that the enclosed submission includes no new matter. The Sequence Listing was prepared with the software FASTSEQ, and conforms to the Patent Office guidelines. Applicant respectfully submits that the subject application is in adherence to 37 CFR §§ 1.821-1.825.

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number RICE-032.

Respectfully submitted,

Dated: May 5, 2005

By 
Carol L. Francis
Registration No 36,513

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

F:\DOCUMENT\RICE\032\Cert re Seq Listing & Prel Amend in resp to Miss Req 4.18.05.RICE-032.doc

ABSTRACT

The present invention relates to antibodies which bind to C5aR and which are useful in diagnostic and therapeutic methods. The antibodies of the present invention are reactive with an extracellular loop of C5aR other than the N-terminal domain and are capable of substantially reducing or inhibiting the binding of C5a to C5aR and functional consequences of neutrophil chemoattractant receptor activation.